J&J inks clinical trial deal with Stand Up To Cancer, latest pharma to join cancer nonprofit study efforts
Johnson & Johnson’s new deal with a leading cancer organization aims to boost diversity in early phase clinical trials. The $5 million sponsorship agreement between Janssen and Stand Up To Cancer (SU2C) will help fund four groups of researchers across the US working to remove barriers to enrolling more patients, especially those in “medically underserved” communities.
SU2C is currently taking applications for the research teams that will work with federally qualified health centers, clinics and local groups that are already partnered with the underrepresented populations. Team applicants who get a second go-around and invitation to submit a full application will have until the end of August. Teams will be selected in September.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.